NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
FOSCAVIR (foscarnet sodium) by Bayer is mechanism of action foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific dna polymerases at concentrations that do not affect cellular dna polymerases. First approved in 1991.
Drug data last refreshed 8h ago
Mechanism of Action
Mechanism of Action Foscarnet exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Foscarnet does not require activation (phosphorylation) by thymidine kinase or…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Bayer
LEVERKUSEN, Germany
Worked on FOSCAVIR at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.